Per Stål

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Open-label Phase 2, Hepatology, Medicine +8

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Mattias Ekstedt, Hannes Hagström, Patrik Nasr et al. · Hepatology · 2014 · 2.2K citations · Full text

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

Hannes Hagström, Patrik Nasr, Mattias Ekstedt et al. · Journal of Hepatology · 2017 · 1K citations

Fibrosis, Metabolic Associated Steatohepatitis, Hepatology +14

Decreased Survival of Subjects With Elevated Liver Function Tests During A 28-Year Follow-Up

Cecilia Söderberg, Per Stål, Johan Askling et al. · Hepatology · 2009 · 747 citations · Full text